DHR

$215.75

Public overview and default valuation.

Log in to track this stock.

Valuation Details
Default assumptions: 10Y forecast, 9% market return, 2.5% terminal growth, 5.44% trendline growth.
Want to create your own valuation? Create a free account.
$213.46

With 20% Margin of Safety (MoS):

$170.77
-20.85% downside
Capital Efficiency
Average Quarterly ROIC
1.44%
Cost of Capital (estimated)8%
Value StatusUnderperforming Capital

The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.

Complete historical ROIC is available with
.
Fundamental Score
33
BearishWeighted across 6 signals
DCF Discount
20.9% premium to price
15
FCF Yield
5.0% trailing FCF yield
74
ROIC vs WACC
ROIC 1.4% vs WACC 8.0% (0.2x)
9
Net Debt / FCF
1.8x net debt to FCF
35
Buybacks
Share count shrinking
80
FCF CAGR (5Y)
1.6% 5Y FCF CAGR
25
Strengths: FCF Yield, Buybacks. Concerns: DCF Discount, ROIC vs WACC.
Narrative Score
80
Strong
Weighted across 4 recent drivers · Last 30 daysVs 6-Month Baseline: High (97th pct)
Trend: Improving upConfidence: 91%Updated: 5h ago
Sources: 70 (News 65 · Analyst 5)
Drivers
30 news sentiment+1.4
33 regulatory scrutiny+1.4
2 earnings beat+0.3
5 analyst reiterations0.0
Other Metrics
P/E42.2
Profit Margin14.7%
Owner Earnings$7.22b
One Dollar Premise25.00%
Debt/Equity0.57
Current Ratio1.61
PEG10.845
Free Cash Flow (in millions)
20062007200820092010201120122013201420152016201720182019202020212022202320242025
$1,685$1,808$2,053$1,989$2,302$2,961$3,873$4,123$4,224$4,315$4,111$4,049$4,606$4,587$6,999$9,652$9,671$8,547$8,080$7,572
How Intrinziq Estimates Fair Value

Intrinziq estimates Danaher Corporation's intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Danaher CorporationHealthcare

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Last updated: Feb 06, 2026
Data sources: Financial Modeling Prep
This valuation is based on assumptions and publicly available data. It is not financial advice or a recommendation to buy or sell any security. Always do your own research before making investment decisions.